Long-term Results of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Real-life Data of 15- and 20-year Survivals from a Single Center
- 1Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Ul. Banacha 1A, 02-097 Warsaw, Poland
- 2Doctoral School of the Medical University of Warsaw, Ul. Żwirki I Wigury 61, 02-091 Warsaw, Poland
Abstract
Allogeneic hematopoietic cell transplantations (allo-HCT) is a procedure with long history and well-documented efficacy in treating various malignant and non-malignant diseases of the hematopoietic system. While there is a potential for late complications even over 10 years following allo-HCT, the data on longer observations are limited due to loss in follow-up, personnel and organizational changes in transplant centers, and focusing on new promising therapies instead of HCT. The study aimed to evaluate 15- and 20-year overall and progression-free survival of allo-HCT recipients in our center. During the inclusion period from 1999 to 2014, we identified 269 allo-HCT recipients. Survival analyses were performed using Kaplan–Meier curves, the Cox proportional hazards model, and the log-rank test. First, we evaluated 15- and 20-year survival rates for the entire cohort of allo-HCT recipients from matched related donor (MRD) and matched unrelated donor (MUD). Then we performed similar analyses for allo-HCT recipients due to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic neoplasms (MDS), non-Hodgkin lymphomas (NHL), and severe aplastic anemia (SAA). It was confirmed that survival benefit continues also during long-term observation. Notably, the plateau effect of PFS was often observed over 20 years following allo-HCT, implying the ability to cure in a relatively large group of patients with otherwise incurable diseases.
Related
- Efficacy of Unrelated Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia: A Single-Center Retrospective Study.
- Rectal colonization with multidrug-resistant organisms in adult acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective, longitudinal, single-center study
- Exercise capacity and handgrip strength following dumbbell-assisted diaphragmatic breathing training in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation: a prospective single-arm study
- The role of allogeneic hematopoietic stem cell transplantation in adults with mature T‐cell lymphomas
- Case Report: SAPHO syndrome mimicking osseous relapse after haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
BibTeX
@article{karaszewski2026longterm,
title = {{Long-term Results of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Real-life Data of 15- and 20-year Survivals from a Single Center}},
author = {Kajetan Karaszewski and Jakub Góra and Monika Paluszewska and Elżbieta Urbanowska and Ewa Karakulska-Prystupiuk and Piotr Boguradzki and Agnieszka Tomaszewska and Grzegorz Władysław Basak and Wiesław Wiktor Jędrzejczak},
journal = {Stem Cell Reviews and Reports},
year = {2026},
month = sep,
doi = {10.1007/s12015-026-11241-2},
url = {https://doi.org/10.1007/s12015-026-11241-2},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Long-term Results of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Real-life Data of 15- and 20-year Survivals from a Single Center
AU - Kajetan Karaszewski
AU - Jakub Góra
AU - Monika Paluszewska
AU - Elżbieta Urbanowska
AU - Ewa Karakulska-Prystupiuk
AU - Piotr Boguradzki
AU - Agnieszka Tomaszewska
AU - Grzegorz Władysław Basak
AU - Wiesław Wiktor Jędrzejczak
PY - 2026
DA - 2026/09/22
JO - Stem Cell Reviews and Reports
DO - 10.1007/s12015-026-11241-2
UR - https://doi.org/10.1007/s12015-026-11241-2
AB - Allogeneic hematopoietic cell transplantations (allo-HCT) is a procedure with long history and well-documented efficacy in treating various malignant and non-malignant diseases of the hematopoietic system. While there is a potential for late complications even over 10 years following allo-HCT, the data on longer observations are limited due to loss in follow-up, personnel and organizational changes in transplant centers, and focusing on new promising therapies instead of HCT. The study aimed to evaluate 15- and 20-year overall and progression-free survival of allo-HCT recipients in our center. During the inclusion period from 1999 to 2014, we identified 269 allo-HCT recipients. Survival analyses were performed using Kaplan–Meier curves, the Cox proportional hazards model, and the log-rank test. First, we evaluated 15- and 20-year survival rates for the entire cohort of allo-HCT recipients from matched related donor (MRD) and matched unrelated donor (MUD). Then we performed similar analyses for allo-HCT recipients due to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic neoplasms (MDS), non-Hodgkin lymphomas (NHL), and severe aplastic anemia (SAA). It was confirmed that survival benefit continues also during long-term observation. Notably, the plateau effect of PFS was often observed over 20 years following allo-HCT, implying the ability to cure in a relatively large group of patients with otherwise incurable diseases.
SN - 2629-3269
SN - 2629-3277
ER -